Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;29(7):1238-1246.
doi: 10.1007/s00044-020-02570-z. Epub 2020 Jun 4.

Screening Trimethoprim Primary Metabolites for Covalent Binding to Albumin

Whitney M Nolte  1 , Robert T Tessman  1 , Jennifer L Goldman  1
Affiliations

Screening Trimethoprim Primary Metabolites for Covalent Binding to Albumin

Whitney M Nolte et al. Med Chem Res. 2020 Jul.

Abstract

Modification of endogenous proteins by drugs and drug metabolites are thought to be a cause of idiosyncratic adverse drug reactions (IADRs). Trimethoprim (TMP) is a commonly prescribed antibiotic that has been implicated in IADRs; however, there is no known mechanism by which this drug or its metabolites modify proteins. This study describes the results of screening trimethoprim and its primary metabolites for the ability to covalently modify human serum albumin (HSA). The first step of the screen was in vitro reactions of the compounds with HSA followed by western blotting with antisera specific to drug-modified proteins. Compounds with positive signal in the western blot were then screened using an untargeted peptide profiling method to discover modified peptides. This strategy identified two sites in HSA that are modified by incubation with a TMP metabolite, α-hydroxy trimethoprim (Cα-OH-TMP).

Keywords: Trimethoprim; adverse drug reaction; metabolism; protein adduct.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Primary trimethoprim metabolites a, TMP b, Cα-OH-TMP c, 4-DM-TMP d, 3-DM-TMP, e, 1-NO-TMP f, 3-NO-TMP
Fig. 2
Fig. 2
Western blot analysis a, TMP and TMP metabolites incubated with HSA b, dose- dependent HSA treatment with Cα-OH-TMP
Fig. 3
Fig. 3
Representative extracted ion chromatograms (EICs) and area boxplots from XCMS data a, EIC for Peptide 1 (681.1) b, EIC for Peptide 2 (816.37) c, boxplot for Peptide 1 (681.1) d, boxplot for Peptide 2 (816.37). Boxes depict the 25–75th percentiles with the whiskers depicting the minimum and maximum values
Fig. 4
Fig. 4
Fragmentation spectra a, spectrum of Peptide 1 (m/z 681.1) showing b and y ions b, zoomed in spectrum of Peptide 1 (m/z 681.1) showing 289.13 reporter c, zoomed out spectrum of Peptide 2 (m/z 816.37) showing 289.13 reporter d, spectrum of Peptide 2 (m/z 816.37) showing b and y ions
Fig. 5
Fig. 5
Cα-NAC-TMP structure showing fragmentation to form 289.13 fragment
Fig. 6
Fig. 6
Measurements of peptides during a time course treatment of HSA with Cα-OH-TMP a, time course EIC for Peptide 1 (681.1) b, time course EIC for Peptide 2 (816.37) c, Mass Lynx area count time course for Peptide 1 (681.1) and Peptide 2 (816.37)
See this image and copyright information in PMC

References

    1. Aldini G, Gamberoni L, Orioli M, Beretta G, Regazzoni L, Maffei Facino R, Carini M (2006) Mass spectrometric characterization of covalent modification of human serum albumin by 4-hydroxy-trans-2-nonenal. Journal of mass spectrometry : JMS 41:1149–1161 - PubMed
    1. Chalkley RJ, Clauser KR (2012) Modification site localization scoring: strategies and performance. Mol Cell Proteomics 11:3–14 - PMC - PubMed
    1. Cho T, Uetrecht J (2017) How Reactive Metabolites Induce an Immune Response That Sometimes Leads to an Idiosyncratic Drug Reaction. Chem Res Toxicol 30:295–314 - PubMed
    1. Damsten MC, de Vlieger JS, Niessen WM, Irth H, Vermeulen NP, Commandeur JN (2008) Trimethoprim: novel reactive intermediates and bioactivation pathways by cytochrome p450s. Chem Res Toxicol 21:2181–2187 - PubMed
    1. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3–16 - PubMed

LinkOut - more resources